文献速递神经肿瘤神经重症

高级别胶质瘤静脉血栓栓塞管理:低分子肝素是否增加颅内出血风险?

Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
PubMed 文献 · Neuro Oncol · 2022-01-01

该回顾性匹配队列研究纳入2005年1月至2016年8月的高级别胶质瘤患者,评估使用低分子肝素治疗静脉血栓栓塞是否增加颅内出血风险。

要点

  • 高级别胶质瘤患者VTE发生率高达30%。
  • LMWH治疗未显著增加1年颅内出血累积发病率。
  • LMWH组与无VTE组中位生存相似。

核心结论

  • 治疗性低分子肝素在高级别胶质瘤合并静脉血栓栓塞患者中未显著增加颅内出血风险。

主要发现

  • 共记录43例可测量颅内出血:LMWH组19例(26%),VTE未抗凝组3例(14%),无VTE组21例(19%)。
  • 无VTE组1年颅内出血累积发病率为13%。
  • 三组中位生存相似。

关键数值与推荐

  • 1年颅内出血累积发病率:LMWH组17%,VTE未抗凝组9%,无VTE组13%。

临床怎么用

  • 对于高级别胶质瘤合并静脉血栓栓塞的患者,使用治疗性低分子肝素时无需过度担忧颅内出血风险显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) occurs in up to 30% of patients with high-grade glioma (HGG). Concern for increased risk of intracranial hemorrhage (ICH) with therapeutic anticoagulation (AC) complicates VTE treatment. Some retrospective studies have reported an increased risk of ICH associated with therapeutic AC; however, effective alternatives to AC are lacking. The aim of our study is to assess the risk of ICH in HGG patients with VTE on low molecular weight heparin (LMWH). METHODS: We performed a retrospective matched cohort study of HGG patients from January 2005 to August 2016. Blinded review of neuroimaging for ICH was performed. For analysis of the primary endpoint, estimates of cumulative incidence (CI) of ICH were calculated using competing risk analysis with death as competing risk; significance testing was performed using the Gray's test. Median survival was estimated using the Kaplan-Meier method. RESULTS: Two hundred twenty patients were included, 88 (40%) with VTE treated with LMWH, 22 (10%) with VTE, not on AC, and 110 (50%) without VTE. A total of 43 measurable ICH was recorded: 19 (26%) in LMWH, 3 (14%) in VTE not on AC, and 21 (19%) in non-VTE cohort. No significant difference was observed in the 1-year CI of ICH in the LMWH cohort and non-AC with VTE group (17% vs 9%; Gray's test, P = .36). Among patients without VTE, the 1-year CI of ICH was 13%. Median survival was similar among all 3 cohorts. CONCLUSIONS: Our data suggest that therapeutic LMWH is not associated with substantially increased risk of ICH in HGG patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Jo J, Donahue J, Sarai G, et al. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk? Neuro Oncol. 2022. PMID: 34383073. doi:10.1093/neuonc/noab198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。